Foghorn Therapeutics Stock Performance
| FHTX Stock | USD 6.13 0.03 0.49% |
On a scale of 0 to 100, Foghorn Therapeutics holds a performance score of 14. The firm shows a Beta (market volatility) of 1.27, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Foghorn Therapeutics will likely underperform. Please check Foghorn Therapeutics' downside variance, and the relationship between the total risk alpha and daily balance of power , to make a quick decision on whether Foghorn Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Foghorn Therapeutics are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of fairly conflicting basic indicators, Foghorn Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.49 | Five Day Return 13.94 | Year To Date Return 33.55 | Ten Year Return (66.17) | All Time Return (66.17) |
1 | Acquisition by Adrian Gottschalk of 300000 shares of Foghorn Therapeutics subject to Rule 16b-3 | 04/25/2025 |
2 | Foghorn Therapeutics Receives Buy Rating from HC Wainwright | 05/01/2025 |
3 | Disposition of 311297 shares by Agresta Samuel of Foghorn Therapeutics at 8.25 subject to Rule 16b-3 | 05/02/2025 |
4 | Foghorn Therapeutics SWOT analysis chromatin pioneers stock faces clinical hurdles - Investing.com | 05/06/2025 |
5 | Ted Myles Joins Cellarity as Chief Executive Officer FHTX Stock News | 05/12/2025 |
6 | FHTX Extends Financial Runway with Substantial Cash Reserves FHTX Stock News | 05/14/2025 |
7 | Foghorn Therapeutics Issues Earnings Results | 05/15/2025 |
8 | Foghorn Therapeutics Inc. Shares Purchased by Sherbrooke Park Advisers LLC | 05/22/2025 |
9 | Acquisition by Lynch Thomas J. Jr. of 32000 shares of Foghorn Therapeutics at 8.23 subject to Rule 16b-3 | 05/28/2025 |
10 | Discretionary transaction by Flagship Pioneering Fund Vii General Partner Llc of 1814915 shares of Foghorn Therapeutics at 1.0E-4 subject to Rule 16b-3 | 06/06/2025 |
11 | Acquisition by Cole Douglas G. of 25000 shares of Foghorn Therapeutics at 4.79 subject to Rule 16b-3 | 06/17/2025 |
12 | Foghorn Therapeutics Inc.s Shares May Have Run Too Fast Too Soon | 07/10/2025 |
13 | Acquisition by Carlos Costa of 35756 shares of Foghorn Therapeutics at 3.72 subject to Rule 16b-3 | 07/17/2025 |
14 | What drives Foghorn Therapeutics Inc. stock price - High-yield investments - Jammu Links News | 07/18/2025 |
| Begin Period Cash Flow | 82 M |
Foghorn Therapeutics Relative Risk vs. Return Landscape
If you would invest 390.00 in Foghorn Therapeutics on April 20, 2025 and sell it today you would earn a total of 223.00 from holding Foghorn Therapeutics or generate 57.18% return on investment over 90 days. Foghorn Therapeutics is currently generating 0.8341% in daily expected returns and assumes 4.6115% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than Foghorn, and 84% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Foghorn Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Foghorn Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Foghorn Therapeutics, and traders can use it to determine the average amount a Foghorn Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1809
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | FHTX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.61 actual daily | 41 59% of assets are more volatile |
Expected Return
| 0.83 actual daily | 16 84% of assets have higher returns |
Risk-Adjusted Return
| 0.18 actual daily | 14 86% of assets perform better |
Based on monthly moving average Foghorn Therapeutics is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Foghorn Therapeutics by adding it to a well-diversified portfolio.
Foghorn Therapeutics Fundamentals Growth
Foghorn Stock prices reflect investors' perceptions of the future prospects and financial health of Foghorn Therapeutics, and Foghorn Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Foghorn Stock performance.
| Return On Equity | -4.7 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (3.85) % | ||||
| Current Valuation | 142.02 M | ||||
| Shares Outstanding | 55.74 M | ||||
| Price To Book | 10.71 X | ||||
| Price To Sales | 14.47 X | ||||
| Revenue | 22.6 M | ||||
| Gross Profit | (67.12 M) | ||||
| EBITDA | (97.17 M) | ||||
| Net Income | (86.62 M) | ||||
| Cash And Equivalents | 373.5 M | ||||
| Cash Per Share | 8.94 X | ||||
| Total Debt | 37.13 M | ||||
| Debt To Equity | 2.19 % | ||||
| Current Ratio | 6.84 X | ||||
| Book Value Per Share | (1.11) X | ||||
| Cash Flow From Operations | (100.41 M) | ||||
| Earnings Per Share | (1.29) X | ||||
| Market Capitalization | 340.02 M | ||||
| Total Asset | 283.98 M | ||||
| Retained Earnings | (558.18 M) | ||||
| Working Capital | 182.61 M | ||||
About Foghorn Therapeutics Performance
Evaluating Foghorn Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Foghorn Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Foghorn Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.31) | (0.32) | |
| Return On Capital Employed | (0.47) | (0.50) | |
| Return On Assets | (0.31) | (0.32) | |
| Return On Equity | 1.90 | 2.00 |
Things to note about Foghorn Therapeutics performance evaluation
Checking the ongoing alerts about Foghorn Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Foghorn Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Foghorn Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 22.6 M. Net Loss for the year was (86.62 M) with loss before overhead, payroll, taxes, and interest of (67.12 M). | |
| Foghorn Therapeutics currently holds about 373.5 M in cash with (100.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Foghorn Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 73.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: What drives Foghorn Therapeutics Inc. stock price - High-yield investments - Jammu Links News |
- Analyzing Foghorn Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Foghorn Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Foghorn Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Foghorn Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Foghorn Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Foghorn Therapeutics' stock. These opinions can provide insight into Foghorn Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Foghorn Stock Analysis
When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.